Seer logo

SeerNASDAQ: SEER

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 December 2020

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$136.21 M
-92%vs. 3y high
49%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
26%vs. sector
-98%vs. 3y high
77%vs. sector

Price

regular market | Fri, 15 Nov 2024 14:30:00 GMT
$2.31-$0.07(-2.94%)

Dividend

No data over the past 3 years
$3.94 M$3.95 M
$3.94 M-$21.33 M

Analysts recommendations

Institutional Ownership

SEER Latest News

Seer to Participate in Upcoming November Investor Conferences
globenewswire.com08 November 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:

Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
zacks.com06 November 2024 Sentiment: NEUTRAL

Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago.

Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024
globenewswire.com31 October 2024 Sentiment: POSITIVE

CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite

Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024
globenewswire.com21 October 2024 Sentiment: POSITIVE

Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale

Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
globenewswire.com22 August 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.

Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
globenewswire.com09 August 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA.

Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
zacks.com08 August 2024 Sentiment: NEUTRAL

Seer, Inc. (SEER) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.37 per share a year ago.

Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
globenewswire.com18 July 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SEER RECEIVES CONTRACT FROM BIOCHAR NOW FOR THE MANUFACTURING OF KILNS AND INTENDS TO OPEN A JV TEXAS BIOCHAR FACILITY
globenewswire.com14 June 2024 Sentiment: POSITIVE

SEER's product and manufacturing division, SEM, LLC, receives its first order from Biochar Now for the manufacturing of 33 kilns totaling approximately $600,000

Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
globenewswire.com11 June 2024 Sentiment: POSITIVE

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation

What type of business is Seer?

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

What sector is Seer in?

Seer is in the Healthcare sector

What industry is Seer in?

Seer is in the Biotechnology industry

What country is Seer from?

Seer is headquartered in United States

When did Seer go public?

Seer initial public offering (IPO) was on 04 December 2020

What is Seer website?

https://seer.bio

Is Seer in the S&P 500?

No, Seer is not included in the S&P 500 index

Is Seer in the NASDAQ 100?

No, Seer is not included in the NASDAQ 100 index

Is Seer in the Dow Jones?

No, Seer is not included in the Dow Jones index

When was Seer the previous earnings report?

No data

When does Seer earnings report?

The next expected earnings date for Seer is 28 February 2025